Evidence map›Paper›PMID 29129052›Full record

ArticleACS chemical neuroscience2018

Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

David A Perrey, Ann M Decker, Yanan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David A PerreyResearch Triangle Institute , Research Triangle Park , North Carolina 27709 , United States.
Ann M DeckerResearch Triangle Institute , Research Triangle Park , North Carolina 27709 , United States.
Yanan ZhangResearch Triangle Institute , Research Triangle Park , North Carolina 27709 , United States.ORCID 0000-0001-7153-4358

Funding

Allosteric Modulation of the CB1 ReceptorR01DA040693 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2016 to 2020
$2.4M
Orexin-1 Receptor Ligands for Drug AddictionR33DA032837 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2014 to 2015
$992k
Orexin-1 Receptor Ligands for Drug AddictionR21DA032837 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZHANG, YANAN · 2012 to 2013
$519k
NIDA NIH HHS R01 DA040693NIDA NIH HHS R21 DA032837NIDA NIH HHS R33 DA032837
6 · The paper itself

Abstract

Orexins are hypothalamic neuropeptides playing important roles in many functions including the motivation of addictive behaviors. Blockade of the orexin-1 receptor has been suggested as a potential strategy for the treatment of drug addiction. We have previously reported OX

Indexed as

AnimalsHypothalamusIntracellular Signaling Peptides and ProteinsNeuropeptidesOrexin Receptor AntagonistsOrexin ReceptorsOrexinsPermeabilityReceptors, G-Protein-CoupledSolubilityTetrahydroisoquinolines1,2,3,4-tetrahydroisoquinolineIntracellular Signaling Peptides and ProteinsNeuropeptidesOrexin Receptor AntagonistsOrexin ReceptorsOrexinsReceptors, G-Protein-CoupledTetrahydroisoquinolinesADMEantagonistOrexinselectivetetrahydroisoquinoline

Identifiers

PMID29129052
PMCPMC6002953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.